Day: May 17, 2023

User Fee Goal Date: October 17, 2023 WALTHAM, Mass., May 17, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmission of a New Drug Application (NDA) for XPHOZAH® (tenapanor) for the control of serum phosphate in adult patients with chronic kidney disease on dialysis who have had an inadequate response or intolerance to a phosphate binder therapy. The FDA has determined that the NDA is a class 2 review, which results in a six-month review period from the date of resubmission. The FDA has set a user fee goal date of October 17, 2023. The company expects XPHOZAH to be commercially...

BETHESDA, Md., May 17, 2023 (GLOBE NEWSWIRE) — Liquidity Services (Nasdaq: LQDT), a leading global commerce company powering the circular economy, today announced Jorge Celaya, Executive Vice President and Chief Financial Officer will participate in the upcoming Barrington Research Virtual Spring Investment Conference on Thursday, May 18, 2023. This virtual conference will bring together investors and management teams from approximately 40 publicly-traded companies operating in diverse sectors such as Business Services, Industrial, Broadcasting, and Financial Services. During the conference, Mr. Celaya will engage in virtual one-on-one meetings with investors, discussing how Liquidity Services pioneers sustainable e-commerce marketplace solutions that power the circular economy to create a better future for organizations, individuals,...

REYKJAVIK, Iceland, May 17, 2023 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley Annual Sustainable Finance Summit on May 22, 2023. Alvotech is scheduled to hold a fireside chat on May 22, 2023 at 10:15 am ET and will host investor meetings at the conference. Alvotech is committed to the promise of biosimilars, which expand patient access to medicines globally and contribute to the overall sustainability of healthcare systems by providing lower cost alternatives to high-priced biologic medicines. Part of Alvotech’s commitment is understanding and mitigating any impact on the natural environment. All of the electrical power for Alvotech’s R&D and manufacturing...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley Annual Sustainable Finance Summit on May 22, 2023. Alvotech is scheduled to hold a fireside chat on May 22, 2023 at 10:15 am ET and will host investor meetings at the conference. Alvotech is committed to the promise of biosimilars, which expand patient access to medicines globally and contribute to the overall sustainability of healthcare systems by providing lower cost alternatives to high-priced biologic medicines.   Part of Alvotech’s commitment is understanding and mitigating any impact on the natural environment. All of the electrical power for Alvotech’s R&D and manufacturing operations is sourced from renewable hydro and geothermal...

May 17, 2023Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA) today announced that the exchange ratio for the dividend for the year 2022 is 1 new common share for every 22.3906 existing common shares. This ratio was based on the volume weighted average price on Euronext Amsterdam of May 11, 12 and 15, 2023, of EUR 19.0020 and was calculated in a manner that the gross dividend in shares will be approximately equal to EUR 0.85. As a result, Philips will issue a total number of 39,334,938 new common shares. Distribution of the dividend with delivery of new common shares and settlement of any fractions in cash, will take place from May 18, 2023. Upon distribution, the total issued share capital will amount to EUR 185,730,004, representing 928,650,020 common shares. Before the end of the year, Philips expects to cancel a total...